A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus
Trial details
- Registry ID
- NCT07482657
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial VirusNCT07482657 | ENTA | Phase 2 | Recruiting | 2026-12Estimated |
| A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe DiseaseNCT07908381 | ENTA | Phase 2, Phase 3 | Recruiting | 2029-07Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |